127500-84-9

Basic information

• Product Name: RO 41-1049 HCL MAO-A INHIBITOR
• Synonyms: RO 41-1049 HCL MAO-A INHIBITOR;RO 41-1049 HYDROCHLORIDE MAO-A INHIBITOR;Ro 41-1049;N-(2-Aminoethyl)-5-(3-fluorophenyl)-4-thiazolecarboxamide;N-(2-Aminoethyl)-5-(3-fluorophenyl)thiazole-4-carboxamide;RO41-1049HCL
• CAS NO: 127500-84-9
• Molecular Formula: C12F1H12N3O1S1
• Molecular Weight: 301.77
• Product Categories: A selective, reversible, orally active inhibitor of MAO-A.
• Mol File: 127500-84-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 493.498 °C at 760 mmHg
• Flash Point: 252.259 °C
• Appearance: white/solid
• Density: 1.312 g/cm³
• Vapor Pressure: 7E-10mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: H2O: soluble
• CAS DataBase Reference: RO 41-1049 HCL MAO-A INHIBITOR(CAS DataBase Reference)
• NIST Chemistry Reference: RO 41-1049 HCL MAO-A INHIBITOR(127500-84-9)
• EPA Substance Registry System: RO 41-1049 HCL MAO-A INHIBITOR(127500-84-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 127500-84-9(Hazardous Substances Data)

Usage

General Description

RO 41-1049 HCL is a potent inhibitor of the enzyme monoamine oxidase A (MAO-A), an important target in the treatment of depression, anxiety, and other psychiatric disorders. MAO-A is responsible for breaking down neurotransmitters such as serotonin, norepinephrine, and dopamine, which play a critical role in regulating mood, emotions, and stress responses. By inhibiting MAO-A, RO 41-1049 HCL increases the levels of these neurotransmitters in the brain, leading to an overall improvement in mood and a reduction in anxiety.However, it is important to note that MAO inhibitors can have potentially serious interactions with certain foods and other medications, so they should be used with caution and under the supervision of a healthcare professional.

InChI:InChI=1/C12H12FN3OS.ClH/c13-9-3-1-2-8(6-9)11-10(16-7-18-11)12(17)15-5-4-14;/h1-3,6-7H,4-5,14H2,(H,15,17);1H

Relevant articles and documents

COMPOUNDS FOR TREATING AND PREVENTING COGNITIVE DISEASES AND DEPRESSION AND METHODS OF MAKING SAME

Ethylenediamine monoamides of the formula R--CO--NH--CH2 --CH2 --NH2. wherein R is one of groups in which R1 is phenyl monohalophenyl, monolower-alkylphenyl, monolower-alkoxypheynl, monotrifluoromethylphenyl, monocyanophenyl or monoaryl-lower-alkoxyphenyl, dihalophenyl, furyl, thienyl or monohalothienyl, R2 is hydrogen, halogen or amino, R3, R5 and R7 each are phenyl, monohalophenyl, dihalophenyl, thienyl, furyl or monohalofuryl, R4 and R6 each are hydrogen or amino and R8 is hydrogen or lower-alkyl, as well as their pharmaceutically usable acid addition salts are disclosed. The compounds have monoamine oxidase inhibiting properties with low toxicity and are useful for the treatment of depressive states and cognitive disorders